December 13, 2022
A health ministry panel on December 12 gave the thumbs-up to the label expansions of two CAR-T cell therapies - Daiichi Sankyo’s Yescarta (axicabtagene ciloleucel) and Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) - to allow their use in the earlier-lines...read more